Aldeyra Therapeutics
ALDX
25 hedge funds and large institutions have $36.2M invested in Aldeyra Therapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 4 reducing their positions, and 5 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 4
99% more capital invested
Capital invested by funds: $18.2M → $36.2M (+$18M)
11% less funds holding
Funds holding: 28 → 25 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
+$5.13M |
| 2 |
PA
Perceptive Advisors
New York
|
+$3.91M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.01M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$1.27M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$726K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.14M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$971K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$172K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$31.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12K |
ALDX Hedge Fund Activity: Q2 2016 in Review
25 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q2 2016, worth a combined $36.2M — up 99% from $18.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ALDX and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 14 added.
The largest buyer was AWM Investment Company, opening a new position worth an estimated $5.13M. The largest seller was Deerfield Management, cutting an estimated $1.14M.
- 25 institutional investors held Aldeyra Therapeutics (ALDX) as of Q2 2016, down from 28 in Q1 2016.
- Funds reported $36.2M of Aldeyra Therapeutics stock for Q2 2016, up 99% quarter-over-quarter.
- 2 funds opened new Aldeyra Therapeutics positions in Q2 2016 and 5 closed out, a net change of -3 holders.
- The largest Aldeyra Therapeutics buyer in Q2 2016 was AWM Investment Company, an estimated $5.13M added.
- The largest Aldeyra Therapeutics seller in Q2 2016 was Deerfield Management, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2016.